Biomarkers for detection and surveillance of bladder cancer

Journal of the Canadian Urological Association

Volumn 2, Issue 3, 2008, Pages 212-221

  Budman, Lorne I ^a   Kassouf, Wassim ^b   Steinberg, Jordan R ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 65649098940     PISSN: 19116470     EISSN: 19116470     Source Type: Journal    
DOI: 10.5489/cuaj.600     Document Type: Article

References (75)

1. Canadian Cancer Society. Canadian cancer statistics 2006. Available: www.cancer.ca/vgn/images/portal/cit-86751114/31/21/935505792cw-2006s tats-en.pdf.pdf (accessed 2008 Apr 10).
2. Rubben H, Lutzeyer W, Fischer N, et al. Natural history and treatment of low and high risk superficial bladder tumors. J Urol 1988;139:283-285
3. Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol 1983;130:1083-1086
4. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000;164:680-684
5. Avritscher EB, Cooksley CD, Grossman HB, et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 2006;68:549-553
6. Lotan Y, Svatek RS, Sagalowsky AI. Should we screen for bladder cancer in a highrisk population? A cost per life-year saved analysis. Cancer 2006;107:982-990
7. Svatek RS, Sagalowsky AI, Lotan Y. Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis. Urol Oncol 2006;24:338-343
8. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003;61:109-18; discussion 118.
9. van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005;47:736-748
10. Dey P. Urinary markers of bladder carcinoma. Clin Chim Acta 2004;340:57-65.
11. Shariat SF, Marberger MJ, Lotan Y, et al. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J Urol 2006;176:919-26; discussion 926.
12. Schroeder GL, Lorenzo-Gomez MF, Hautmann SH, et al. A side by side comparison of cytology and biomarkers for bladder cancer detection. J Urol 2004;172:1123-1126
13. Friedman GD, Carroll PR, Cattolica EV, et al. Can hematuria be a predictor as well as a symptom or sign of bladder cancer? Cancer Epidemiol Biomarkers Prev 1996;5:993-996
14. Messing EM, Vaillancourt A. Hematuria screening for bladder cancer. J Occup Med 1990;32:838-845
15. Britton JP, Dowell AC, Whelan P, et al. A community study of bladder cancer screening by the detection of occult urinary bleeding. J Urol 1992;148:788-790
16. Khan MA, Shaw G, Paris AM. Is microscopic haematuria a urological emergency? BJU Int 2002;90:355-357
17. Hemastix [package insert]. Leverkusen (DE): Bayer; 2007.
18. Halling KC, King W, Sokolova IA, et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 2002;167:2001-2006
19. Parekattil SJ, Fisher HA, Kogan BA. Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer. J Urol 2003;169:917-920
20. Bhuiyan J, Akhter J, O'Kane DJ. Performance characteristics of multiple urinary tumor markers and sample collection techniques in the detection of transitional cell carcinoma of the bladder. Clin Chim Acta 2003;331:69-77.
21. Saad A, Hanbury DC, McNicholas TA, et al. A study comparing various noninvasive methods of detecting bladder cancer in urine. BJU Int 2002;89:369-373
22. Boman H, Hedelin H, Jacobsson S, et al. Newly diagnosed bladder cancer: the relationship of initial symptoms, degree of microhematuria and tumor marker status. J Urol 2002;168:1955-1959
23. Abd El Gawad IA, Moussa HS, Nasr MI, et al. Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer. J Egypt Natl Canc Inst 2005;17: 193-202.
24. Babjuk M, Kostirova M, Mudra K, et al. Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder. Eur Urol 2002;41:34-39
25. Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005;293:810-816
26. Grossman HB, Soloway M, Messing E, et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 2006;295:299-305.
27. Hautmann S, Toma M, Lorenzo Gomez MF, et al. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. Eur Urol 2004;46:466-471
28. Krause FS, Rauch A, Schrott KM, et al. Clinical decisions for treatment of different staged bladder cancer based on multitarget fluorescence in situ hybridization assays? World J Urol 2006;24:418-422
29. Kumar A, Kumar R, Gupta NP. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer. Jpn J Clin Oncol 2006;36:172-175
30. Laudadio J, Keane TE, Reeves HM, et al. Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice. BJU Int 2005;96:1280-1285
31. Lodde M, Mian C, Comploj E, et al. uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma. Urology 2006;67:950-954
32. Messing EM, Teot L, Korman H, et al. Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States. J Urol 2005;174:1238-1241
33. Mian C, Maier K, Comploj E, et al. uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses. Cancer 2006;108:60-65
34. Moonen PM, Kiemeney LA, Witjes JA. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer. Eur Urol 2005;48:951-6; discussion 956.
35. Sarosdy MF, Kahn PR, Ziffer MD, et al. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol 2006;176: 44-47
36. Shariat SF, Zippe C, Ludecke G, et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol 2005;173:1518-1525
37. Sun Y, He DL, Ma Q, et al. Comparison of seven screening methods in the diagnosis of bladder cancer. Chin Med J (Engl) 2006;119:1763-1771
38. Tetu B, Tiquert R, Harel F, et al. ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. Mod Pathol 2005;18:83-89
39. Toma MI, Friedrich MG, Hautmann SH, et al. Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer. World J Urol 2004;22:145-149
40. Tritschler S, Scharf S, Karl A, et al. Validation of the diagnostic value of NMP22 BladderChek Test as a marker for bladder cancer by photodynamic diagnosis. Eur Urol 2007;51:403-408
41. Tsui KH, Chen SM, Wang TM, et al. Comparisons of voided urine cytology, nuclear matrix protein-22 and bladder tumor associated antigen tests for bladder cancer of geriatric male patients in Taiwan, China. Asian J Androl 2007;9:711-715
42. Chang YH, Wu CH, Lee YL, et al. Evaluation of nuclear matrix protein-22 as a clinical diagnostic marker for bladder cancer. Urology 2004;64:687-692
43. Bollmann M, Heller H, Bankfalvi A, et al. Quantitative molecular urinary cytology by fluorescence in situ hybridization: A tool for tailoring surveillance of patients with superficial bladder cancer? BJU Int 2005;95:1219-1225
44. Constantinou M, Binka-Kowalska A, Borkowska E, et al. Application of multiplex FISH, CGH and MSSCP techniques for cytogenetic and molecular analysis of transitional cell carcinoma (TCC) cells in voided urine specimens. J Appl Genet 2006;47:273-275
45. Halling KC, King W, Sokolva IA, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000;164:1768-1775
46. Bastacky S, Ibrahim S, Wilcyznski SP, et al. The accuracy of urinary cytology in daily practice. Cancer 1999;87:118-128
47. Kinders R, Jones T, Root R, et al. Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res 1998;4:2511-2520
48. Sharma S, Zippe CD, Pandrangi L, et al. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 1999;162:53-57
49. Raitanen MP, Hellstrom P, Martilla T, et al. Effect of intravesical instillations on the human complement factor H related protein (BTA stat) test. Eur Urol 2001;40:422-426 (Pubitemid 34032820)
50. Liou LS. Urothelial cancer biomarkers for detection and surveillance. Urology 2006;67(Suppl 1):25-33; discussion 33-34
51. Berezney R, Coffey DS. Identification of a nuclear protein matrix. Biochem Biophys Res Commun 1974;60:1410-1417
52. Pardoll DM, Vogelstein B, Coffey DS. A fixed site of DNA replication in eukaryotic cells. Cell 1980;19:527-536 (Pubitemid 10152900)
53. Gordon JN, Shu WP, Schlussel RN, et al. Altered extracellular matrices influence cellular processes and nuclear matrix organizations of overlying human bladder urothelial cells. Cancer Res 1993;53:4971-4977
54. Fey EG, Krochmalnic G, Penman S. The nonchromatin substructures of the nucleus: the ribonucleoprotein (RNP)-containing and RNP-depleted matrices analyzed by sequential fractionation and resinless section electron microscopy. J Cell Biol 1986;102:1654-1665
55. Fradet Y, Lockhard C. Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark. Can J Urol 1997;4:400-405
56. ImmunoCyt/uCyt+ [package insert]. Québec: DiagnoCure; 2006.
57. Mian C, Lodde M, Comloj E, et al. The value of the ImmunoCyt/uCyt+ test in the detection and follow-up of carcinoma in situ of the urinary bladder. Anticancer Res 2005;25:3641-3644
58. Zellweger T, Benz G, Cathomas G, et al. Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. Int J Cancer 2006;119:1660-1665
59. Hopman AH, Moesker O, Smeets AW, et al. Numerical chromosome 1, 7, 9, and 11 aberrations in bladder cancer detected by in situ hybridization. Cancer Res 1991;51: 644-651
60. Hopman AH, Poddighe PJ, Smeets AW, et al. Detection of numerical chromosome aberrations in bladder cancer by in situ hybridization. Am J Pathol 1989;135:1105-1117
61. Waldman FM, Carroll PR, Kerschmann R, et al. Centromeric copy number of chromosome 7 is strongly correlated with tumor grade and labeling index in human bladder cancer. Cancer Res 1991;51:3807-3813
62. Daniely M, Rona R, Kaplan T, et al. Combined analysis of morphology and fluorescence in situ hybridization significantly increases accuracy of bladder cancer detection in voided urine samples. Urology 2005;66:1354-1359
63. Junker K, Fritsch T, Hartmann A, et al. Multicolor fluorescence in situ hybridization (M-FISH) on cells from urine for the detection of bladder cancer. Cytogenet Genome Res 2006;114:279-283
64. Kipp BR, Karnes RJ, Brankley SM, et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 2005;173:401-404
65. Bubendorf L, Grilli B, Sauter G, et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 2001;116:79-86.
66. Pode D, Shapiro A, Wald M, et al. Noninvasive detection of bladder cancer with the BTA stat test. J Urol 1999;161:443-446
67. Friedrich MG, Hellstern A, Toma MI, et al. Are false-positive urine markers for the detection of bladder carcinoma really wrong or do they predict tumor recurrence? Eur Urol 2003;43:146-50; discussion 150-151
68. Diamandis EP. How are we going to discover new cancer biomarkers? A proteomic approach for bladder cancer. Clin Chem 2004;50:793-795
69. Friedman KM, Fox BA. The promising future of proteomics in cancer diagnosis and treatment. Eur J Gastroenterol Hepatol 2005;17:701-703
70. Celis JE, Ostergaard M, Basse B, et al. Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas. Cancer Res 1996;56:4782-4790
71. Ostergaard M, Rasmussen HH, Nielsen HV, et al. Proteome profiling of bladder squamous cell carcinomas: identification of markers that define their degree of differentiation. Cancer Res 1997;57:4111-4117
72. Celis JE, Celis P, Ostergaard M, et al. Proteomics and immunohistochemistry define some of the steps involved in the squamous differentiation of the bladder transitional epithelium: a novel strategy for identifying metaplastic lesions. Cancer Res 1999;59: 3003-3009
73. Chapman K. The ProteinChip Biomarker System from Ciphergen Biosystems: a novel proteomics platform for rapid biomarker discovery and validation. Biochem Soc Trans 2002;30:82-87
74. Vlahou A, Fountoulakis M. Proteomic approaches in the search for disease biomarkers. J Chromatogr B Analyt Technol Biomed Life Sci 2005;814:11-19
75. Vlahou A, Schellhammer PF, Mendrinos S, et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001;158:1491-1502